Loading market data...
Latest Top News
Show more
Concord Biotech’s Dholka Facility: Four USFDA Observations, Countless Opportunities for Compliance
Concord Biotech Limited has released a press release announcing that it has successfully completed a routine USFDA inspection of its Dholka manufacturing plant. The inspection process was carried out between April 28 and May 2, 2025, for five working days. After the process was completed, the USF...
Stay Ahead – Explore Now! Metropolis Healthcare Broadens Footprint in Maharashtra with Ambika Pathology Buyout






